Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06764368 | Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors | not yet recruiting | Phase 2 | 39 | Beijing Chest HospitalOTHER | 0 | Jan 8, 2025 | clinicaltrials |
| NCT02724540 | Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver | completed | Phase 2 | 162 | Abramson Cancer Center at Penn MedicineOTHER | 4 | Jan 6, 2025 | clinicaltrials |
| NCT03278379 | Avelumab in G2-3 NET(NET-002) | completed | Phase 2 | 17 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02185443 | Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases | recruiting | Phase 2 | 43 | University of Sao PauloOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02749331 | Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy(RADNET) | active not recruiting | Phase 1 / Phase 2 | 35 | Uppsala UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03034200 | Phase 2 Study of ONC201 in Neuroendocrine Tumors | completed | Phase 2 | 30 | Peter AndersonOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05568017 | Neoadjuvant PRRT With Y-90-DOTATOC in pNET(NeoNet) | terminated | Phase 2 | 11 | European Institute of OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05554003 | Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study(MeTe) | recruiting | Phase 2 | 46 | European Institute of OncologyOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03070301 | A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors | completed | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT01678664 | Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors(EVACEL) | completed | Phase 2 | 74 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03454763 | Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors(LUTHREE) | active not recruiting | Phase 2 | 618 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04166006 | A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.(RaC-Ad) | recruiting | Phase 2 | 51 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05176665 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | unknown | Phase 1 / Phase 2 | 152 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT02754297 | Personalized PRRT of Neuroendocrine Tumors(P-PRRT) | active not recruiting | Phase 2 | 275 | CHU de Quebec-Universite LavalOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04524208 | A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3(CABONEN) | unknown | Phase 2 | 45 | Karsten GavenisOTHER | 2 | Aug 13, 2024 | clinicaltrials |
| NCT06045260 | "Receptor Radionuclide Therapy With 177Lu-DOTATOC(LUFOR) | recruiting | Phase 2 | 100 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06540937 | Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT02923934 | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers | completed | Phase 2 | 120 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06472388 | Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors(EVENET) | recruiting | Phase 2 | 100 | AC Camargo Cancer CenterOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03038308 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | completed | Phase 1 / Phase 2 | 16 | Columbia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05396118 | Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients | unknown | Phase 2 | 15 | Rigshospitalet, DenmarkOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT03870399 | Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression(HORMONET) | completed | Phase 2 | 23 | AC Camargo Cancer CenterOTHER | 2 | May 6, 2024 | clinicaltrials |
| NCT04614766 | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors(SPORE-3) | withdrawn | Phase 1 / Phase 2 | 0 | David BushnellOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT01466036 | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT01525082 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | Shaheen ShaguftaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03420521 | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT02399215 | Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 32 | Roswell Park Cancer InstituteOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT02859064 | Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | terminated | Phase 2 | 6 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06155994 | 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours | completed | Phase 1 / Phase 2 | 12 | Medical University InnsbruckOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05709171 | Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms | unknown | Phase 2 | 200 | Rigshospitalet, DenmarkOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02893930 | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT01782443 | Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT02592707 | Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs | terminated | Phase 1 / Phase 2 | 40 | IpsenINDUSTRY | 8 | Jul 19, 2023 | clinicaltrials |
| NCT00427349 | AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03043664 | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors(PLANET) | completed | Phase 1 / Phase 2 | 22 | Duke UniversityOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04385992 | Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET(NeoLuPaNET) | completed | Phase 2 | 31 | IRCCS San RaffaeleOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04543955 | Telotristat With Lutathera in Neuroendocrine Tumors | terminated | Phase 2 | 1 | Lowell Anthony, MDOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT00442533 | Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors | completed | Phase 2 / Phase 3 | 200 | Radio Isotope Therapy of AmericaOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT01237457 | 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms | completed | Phase 2 | 143 | Ebrahim S DelpassandOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04276597 | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.(PUTNET) | withdrawn | Phase 2 | 0 | Excel Diagnostics and Nuclear Oncology CenterOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT01253161 | Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT04915144 | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | withdrawn | Phase 2 | 0 | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 8, 2025source: clinicaltrials